BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15041241)

  • 1. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Wu X; Yang Y
    J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Aoyama RG
    Chirality; 1999; 11(4):286-90. PubMed ID: 10224655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
    Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
    Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
    Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
    Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
    Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
    Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
    Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
    Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
    Plooy AC; van Dijk M; Lohman PH
    Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
    Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
    Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte.
    Hasinoff BB; Venkataram S; Singh M; Kuschak TI
    Xenobiotica; 1994 Oct; 24(10):977-87. PubMed ID: 7900413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+.
    Balcarová Z; Kaspárková J; Zákovská A; Nováková O; Sivo MF; Natile G; Brabec V
    Mol Pharmacol; 1998 May; 53(5):846-55. PubMed ID: 9584210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.